Consistently, ecDNA-harboring, MYCN-amplified neuroblastomas exhibited the lowest HRDetect probability scores, an alternative measure of HRR activity,51 across our cohort, with a median score of 1% and no patient with a score >70% (Figures 3A, 3C, and 3E; Table S8). This evidence concerns the gene MYCN and neuroblastoma.